Nanoparticle cisplatin chemotherapy targeting urinary bladder tumors and their vascularization

What is it about?

A principal clinical use of cisplatin is for urinary bladder carcinoma—there are 16,000 deaths annually in the U.S. due to this cancer. Targeted delivery of drugs directly to cancer cells, sparing normal cells, is of current interest in oncology. We report enhanced cisplatin delivery to urinary bladder cancer tumors in mice and increased drug efficacy by using a tumor-targeting nanoparticle formulation, Nano-diamino-tetrac (NDAT), to deliver cisplatin.

Featured Image